Sprouting of corticospinal tract axons from the contralateral hemisphere into the denervated side of the spinal cord is associated with functional recovery in adult rat after traumatic brain injury and erythropoietin treatment.
Erythropoietin (EPO) promotes functional recovery after traumatic brain injury (TBI). This study was designed to investigate whether EPO treatment promotes contralateral corticospinal tract (CST) plasticity in the spinal cord in rats after TBI. Biotinylated dextran amine (BDA) was injected into the right sensorimotor cortex to anterogradely label the CST. TBI was induced by controlled cortical impact over the left parietal cortex immediately after BDA injections. EPO (5000 U/kg) or saline was administered intraperitoneally at Days 1, 2, and 3 post-injury. Neurological function was assessed using a modified neurological severity score (mNSS) and footfault tests. Animals were sacrificed 35 days after injury and brain sections stained for histological analysis. Compared to the saline treatment, EPO treatment significantly improved sensorimotor functional outcome (lower mNSS and reduced footfaults) from Days 7 to 35 post-injury. TBI alone significantly stimulated contralateral CST axon sprouting toward the denervated gray matter of the cervical and lumbar spinal cord; however, EPO treatment further significantly increased the axon sprouting in TBI rats although EPO treatment did not significantly affect axon sprouting in sham animals. The contralesional CST sprouting was highly and positively correlated with sensorimotor recovery after TBI. These data demonstrate that CST fibers originating from the contralesional intact cerebral hemisphere are capable of sprouting into the denervated spinal cord after TBI and EPO treatment, which may at least partially contribute to functional recovery.
Zhang
Yanlu
Y
Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA.
Xiong
Ye
Y
Mahmood
Asim
A
Meng
Yuling
Y
Liu
Zhongwu
Z
Qu
Changsheng
C
Chopp
Michael
M
D000818:Animals; D001369:Axons / Q000187:drug effects / Q000473:pathology; D001710:Biotin / Q000031:analogs & derivatives; D001930:Brain Injuries / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003911:Dextrans; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000627:therapeutic use*; D007839:Functional Laterality / Q000187:drug effects*; D006400:Hematocrit / Q000379:methods; D006614:Hindlimb / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D009460:Neurologic Examination / Q000379:methods; D011597:Psychomotor Performance / Q000187:drug effects; D011712:Pyramidal Tracts / Q000187:drug effects* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function / Q000187:drug effects*; D013116:Spinal Cord / Q000473:pathology*; D013223:Statistics as Topic; D013997:Time Factors
D003911:Dextrans; C076397:biotinylated dextran amine; D004921:Erythropoietin; D001710:Biotin